Factor XI inhibitor antisense oligonucleotide has been shown to reduce the risk of venous thrombosis in patients undergoing primary unilateral total knee arthroplasty, according to a Medscape report.
The factor XI inhibitor is manufactured by Isis Pharmaceuticals. "This study really shows for the first time that if you target factor XI, you can push venous thrombosis rates down to 4 percent, which has never been done before," said study author Harry R. Büller, MD, PhD, according to the report.
The study compared the use of the factor XI inhibitor with enoxaparin.
Read the full study here.